Adamas launches pivotal trial of CNS drug
By Michael Fitzhugh
Tuesday, June 10, 2014
Adamas Pharmaceuticals Inc., primed by a recent $25 million milestone payment on an unrelated program, is starting a pivotal phase III study to test the ability of ADS-5102, its experimental extended-release formulation of generic drug amantadine, to quell involuntary movements tied to Parkinson's disease (PD) treatment.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.